Introduction: Cystic echinococcosis (CE), a chronic disabling parasitic zoonosis, poses a great threat to public health and livestock production and causes huge economic losses globally. The commercial Quil-A-adjuvanted Eg95 vaccine was empirically effective for CE control; however, it is expensive and has side effects and insufficient immunity. Purpose: This study aimed to employ a novel adjuvant consisting of a delivery system and an immune potentiator and assess its adjuvanticity to Eg95 antigen, thereby developing a safe and cost-effective novel vaccine against the disease. Methods: A ferritin-based Eg95 nanoparticle antigen was prepared and then mixed with a plasmid containing the TLR9 agonist CpG to formulate a novel nanovaccine. The safety and efficacy of the vaccine were evaluated in vitro and in vivo. Results: The nanovaccine induced potent and enduring Eg95-specific humoral and cellular immune responses, as well as protective immunity-associated Th1 polarization supported by the higher ratios of IgG2a/IgG1 and IFN-γ/IL-4. Meanwhile, this nanovaccines exhibited favorable safety and economic profiles. Conclusion: Our data demonstrated that the ferritin-CpG hybrid is a promising combination adjuvant to upgrade the traditional Quil-A and this combination adjuvant-based nanovaccine presents good potential as an alternative to the commercial one for practical CE control.
In this study, we reported the isolation, identification, and molecular characteristics of nine BVDV strains that were isolated from the serum of persistently infected cattle. The new strains were designated as BVDV TJ2101, TJ2102, TJ2103, TJ2104, TJ2105, TJ2106, TJ2107, TJ2108 and TJ2109. The TJ2102 and TJ2104 strains were found to be cytopathic BVDV, and the other strains were non-cytopathic BVDV. An alignment and phylogenetic analysis showed that the new isolates share 92.2–96.3% homology with the CP7 strain and, thus, were classified as the BVDV-1b subgenotype. A recombination analysis of the genome sequences showed that the new strains could be recombined by the major parent BVDV-1a NADL strain and the minor parent BVDV-1m SD-15 strain. Some genome variations or unique amino acid mutations were found in 5′-UTR, E0 and E2 of these new isolates. In addition, a potential linear B cell epitopes prediction showed that the potential linear B cell epitope at positions 56–61 is highly variable in BVDV-1b. In conclusion, the present study has identified nine strains of BVDV from persistently infected cattle in China. Further studies on the virulence and pathogenesis of these new strains are recommended.
3 December 2024 in Probiotics and Antimicrobial Proteins